▲ +21.69% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Axonics in the last 3 months. The average price target is $65.75, with a high forecast of $77.00 and a low forecast of $57.00. The average price target represents a 21.69% upside from the last price of $54.03.
The current consensus among 7 polled investment analysts is to buy stock in Axonics. This Buy consensus rating has held steady for over two years.
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, France, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is headquartered in Irvine, California.